{"id":54244,"date":"2023-02-25T14:03:05","date_gmt":"2023-02-25T13:03:05","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/octave-presents-data-from-nine-company-and-partner-abstracts-at-actrims-forum-2023\/"},"modified":"2023-02-25T14:03:05","modified_gmt":"2023-02-25T13:03:05","slug":"octave-presents-data-from-nine-company-and-partner-abstracts-at-actrims-forum-2023","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/octave-presents-data-from-nine-company-and-partner-abstracts-at-actrims-forum-2023\/","title":{"rendered":"Octave Presents Data from Nine Company and Partner Abstracts at ACTRIMS Forum 2023"},"content":{"rendered":"
\n

\nReal-world data sets show components of value-based care, use of Octave\u2019s Multiple Sclerosis Disease Activity test and deep scan biomarker screening capabilities to evaluate evidence of disability, disease activity, and disease progression<\/i>\n<\/p>\n

\nStudy presented in partnership with the Michigan Institute for Neurological Disorders highlights the promise of the Multiple Sclerosis Disease Activity test for patients in routine clinical use<\/i>\n<\/p>\n

MENLO PARK, Calif.–(BUSINESS WIRE)–Octave<\/a>, a leading digital health sciences company that delivers a new standard for managing multiple sclerosis (MS) and other neurodegenerative diseases, today announced the presentation of nine abstracts at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Conference 2023<\/a>. The abstracts, presented in partnership with several of Octave\u2019s premier research partners, included data on the company\u2019s MRI Insights program as well as applications of the company\u2019s clinically-validated Multiple Sclerosis Disease Activity (MSDA) test, including real-world data as well as new deep scan proteomic approaches. Research collectively underscored the strength and utility of the company\u2019s Precision Care Solution for MS, which commercially launched<\/a> in October 2022 and delivers quantitative, objective insights to better characterize individual patients\u2019 underlying biology, response to therapeutic interventions, radiographic status, and evolving symptoms.\n<\/p>\n

<\/a><\/p>\n

\n\u201cWe are thrilled to follow a very successful ECTRIMS meeting with an expanded body of research at this year\u2019s ACTRIMS conference,\u201d said William Hagstrom, Founder and Chief Executive Officer of Octave. \u201cWe\u2019re adding to findings that have repeatedly shown the validity, quality, and adaptability of our solution, and now, we\u2019re beginning to show real world applications as our clinical and research partners integrate these capabilities into their practices. The proof points we are building together have the potential to create a new standard of care for patients, and we\u2019re grateful to our collaborators as they help us advance our mission to deliver holistic, comprehensive, biological, and contextual metrics that bring scientific clarity to MS.\u201d\n<\/p>\n

\nBIOMARKER POSTERS<\/b>\n<\/p>\n

\nFirst, Octave presented insights on the company\u2019s first of its kind, MS-specific multivariate biomarker assay panel and leveraging deep scan proteomics in multiple posters at ACTRIMS Forum 2023. Highlights include a poster titled Proteomic Biomarker Panel for Gauging Multiple Sclerosis Disease Activity: A Case Series from Real-World Use<\/a> <\/b>(P035), Gonyou, T., et al., <\/i>presented in partnership with the Michigan Institute for Neurological Disorders (MIND), describing real-world clinical experience using Octave\u2019s MSDA test. The presentation reported on how the results from five diverse patient case studies reconciled with clinical presentation, radiographic evidence, and patient history, and how these additional insights into the underlying biology of MS support clinical decisions.\n<\/p>\n

\n\u201cWe are excited to share results demonstrating that disease activity scores from the MSDA test appear to correlate with relapses and efficacy of therapy in a real-world setting,\u201d said Taylor Gonyou, DO, Multiple Sclerosis Fellow at MIND and first author on the poster. \u201cThis test can be used to verify stability and may support the clinical decision to alter therapy. The ability to follow patients longitudinally will provide additional insights into patients\u2019 disease activity, and allow treating neurologists to be confident in clinical decisions.\u201d\n<\/p>\n

\nAdditional posters related to Octave\u2019s multivariate biomarker assay panel include:\n<\/p>\n